[go: up one dir, main page]

Leiomyosarcoma

"Leiomyosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

expand / collapse MeSH information
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)


expand / collapse Publications
This graph shows the total number of publications written about "Leiomyosarcoma" by people in this website by year, and whether "Leiomyosarcoma" was a major or minor topic of these publications.
Below are the most recent publications written about "Leiomyosarcoma" by people in Profiles.
  1. Deep multi-omics integration approach reveals new molecular features of uterine leiomyosarcoma. Biochim Biophys Acta Mol Basis Dis. 2025 Mar; 1871(3):167632.
    View in: PubMed
  2. Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic review and meta-analysis. Gynecol Oncol. 2024 Dec; 191:219-227.
    View in: PubMed
  3. A congenital periocular leiomyosarcoma in a dairy calf. J Vet Diagn Invest. 2024 Nov; 36(6):937-940.
    View in: PubMed
  4. TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group. ESMO Open. 2024 Aug; 9(8):103667.
    View in: PubMed
  5. COL1A1::PDGFB fusion-associated uterine fibrosarcoma: A case report and review of the literature. Cancer Rep (Hoboken). 2024 02; 7(2):e1969.
    View in: PubMed
  6. PD-1 Inhibition in metastatic high tumour mutational burden (TMB) leiomyosarcoma with clinicopathological correlates. BMJ Case Rep. 2023 Nov 17; 16(11).
    View in: PubMed
  7. Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment. Clin Cancer Res. 2023 11 14; 29(22):4679-4684.
    View in: PubMed
  8. Subcutaneous Leiomyosarcoma: An Aggressive Malignancy Portending a Significant Risk of Metastasis and Death. Am J Surg Pathol. 2023 12 01; 47(12):1417-1424.
    View in: PubMed
  9. Uterine Leiomyosarcoma With Osteoclast-like Giant Cells: Report of 2 Cases and Review of Literature. Int J Gynecol Pathol. 2024 Mar 01; 43(2):182-189.
    View in: PubMed
  10. MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness. Mol Oncol. 2024 Apr; 18(4):850-865.
    View in: PubMed